- Home
- PHAR vs ACEL Comparison
PHAR vs ACEL Comparison
Compare PHAR & ACEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- ACEL
- Stock Information
- Founded
- PHAR 1988
- ACEL 2009
- Country
- PHAR Netherlands
- ACEL United States
- Employees
- PHAR N/A
- ACEL N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- ACEL Services-Misc. Amusement & Recreation
- Sector
- PHAR Health Care
- ACEL Consumer Discretionary
- Exchange
- PHAR Nasdaq
- ACEL Nasdaq
- Market Cap
- PHAR 951.7M
- ACEL 934.8M
- IPO Year
- PHAR N/A
- ACEL N/A
- Fundamental
- Price
- PHAR $14.34
- ACEL $10.31
- Analyst Decision
- PHAR Strong Buy
- ACEL Buy
- Analyst Count
- PHAR 3
- ACEL 1
- Target Price
- PHAR $30.00
- ACEL $16.00
- AVG Volume (30 Days)
- PHAR 14.9K
- ACEL 263.2K
- Earning Date
- PHAR 10-23-2025
- ACEL 10-29-2025
- Dividend Yield
- PHAR N/A
- ACEL N/A
- EPS Growth
- PHAR N/A
- ACEL N/A
- EPS
- PHAR N/A
- ACEL 0.40
- Revenue
- PHAR $339,836,000.00
- ACEL $1,279,563,000.00
- Revenue This Year
- PHAR $17.44
- ACEL $9.91
- Revenue Next Year
- PHAR $8.46
- ACEL $4.73
- P/E Ratio
- PHAR N/A
- ACEL $26.18
- Revenue Growth
- PHAR 22.44
- ACEL 7.00
- 52 Week Low
- PHAR $7.31
- ACEL $9.02
- 52 Week High
- PHAR $17.08
- ACEL $13.28
- Technical
- Relative Strength Index (RSI)
- PHAR 50.39
- ACEL 30.79
- Support Level
- PHAR $14.22
- ACEL $10.87
- Resistance Level
- PHAR $16.29
- ACEL $11.21
- Average True Range (ATR)
- PHAR 0.50
- ACEL 0.22
- MACD
- PHAR -0.13
- ACEL -0.08
- Stochastic Oscillator
- PHAR 37.30
- ACEL 2.92
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ACEL Accel Entertainment Inc.
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.